Trying to find 'In Vanda's Room' tonight? We’ve rounded up platforms and services with rental, purchase, and subscription options, so you can find the right fit. Right now in the US, 'In Vanda's Room' ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. News of an update from the U.S. Food and Drug ...
Aggregate retail net buying has fallen to its weakest pace since the Covid era despite markets hovering near all-time highs, ...
Vanda Pharmaceuticals has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Now, following a lawsuit and a protracted back-and ...
Vanda Pharmaceuticals (VNDA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $1.84 per share a year ago.
On Tuesday, as the S&P 500 broke its days-long losing streak, retail investors had their weakest day of stock buying — with just $387 million of inflows — since Joe Biden's election rally and the 2020 ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) took another ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The D.C. biotech grew revenue for its products — in a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The decision comes after the D.C. biotech and the FDA ...
Vanda Pharmaceuticals (VNDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.21 per share a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results